Physician profile
James Lin
NPI 1164764544
$11,859.79
in general payments reported to CMS, 2019-2025
16 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $299 · 2021: $75.74 · 2022: $435 · 2023: $560 · 2024: $9,714 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,825 · Food and Beverage: $1,967 · Travel and Lodging: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,825.00 |
| Food and Beverage | $1,967.30 |
| Travel and Lodging | $737.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,636.59 | 2019-2025 | Xolair, Vabysmo, Susvimo |
| Ocular Therapeutix, INC. | $1,480.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $408.77 | 2021-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $299.11 | 2020 | |
| Novartis Pharmaceuticals Corporation | $277.34 | 2019 | |
| Coherus Oncology, INC. | $158.87 | 2023 | |
| Abbvie INC. | $142.02 | 2022 | |
| Lkc Technologies, INC. | $116.08 | 2023 | |
| Apellis Pharmaceuticals, INC. | $115.08 | 2024 | Syfovre |
| Carl Zeiss Meditec, INC. | $92.78 | 2019 | |
| Genentech, INC. | $32.19 | 2024 | Susvimo, Vabysmo |
| Sandoz INC. | $27.82 | 2024 | Cimerli |
| Astellas Pharma US INC | $24.86 | 2024 | Izervay |
| Nuvasive, INC. | $21.31 | 2023 | Reline |
| Allergan, INC. | $13.77 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.